Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study

Citation data:

Hepatology, Vol: 64, Issue: 2

Publication Year:
2016

No metrics available.

Repository URL:
https://academicworks.medicine.hofstra.edu/articles/2612
Author(s):
Kwo, P.; Gitlin, N.; Nahass, R.; Bernstein, D.; Etzkorn, K.; Rojter, S.; Schiff, E.; Davis, M.; Ruane, P.; Witek, J.; +8 additional authors Show More Hide
Tags:
Science & Technology; Life Sciences & Biomedicine; Gastroenterology & Hepatology; TREATMENT-NAIVE PATIENTS; PEGYLATED INTERFERON; CHRONIC HCV; INFECTION; RIBAVIRIN; DASABUVIR; TRIAL; ABT-450/R-OMBITASVIR; LEDIPASVIR; PEGINTERFERON; Hepatology
article description
By P. Kwo, N. Gitlin, R. Nahass, et al., Published on 01/01/16